There is a part of healthcare that patients rarely see.
It happens before a medicine reaches a pharmacy, before a specialty treatment reaches an oncology center and before a pharmaceutical company can deliver its products to the providers who need them.
It is the infrastructure connecting the healthcare industry.
McKesson operates inside that infrastructure.
The company distributes pharmaceuticals and medical products, supports healthcare providers, operates prescription technology businesses and increasingly participates in oncology, specialty care and biopharma services.
In fiscal 2026, McKesson generated US$403.4 billion in revenue, up 12% from the previous year. Adjusted earnings per share increased 18% to US$39.11, while free cash flow reached US$5.4 billion.
But the most interesting part of McKesson today is not the size of its distribution business.
It is how the company is gradually moving deeper into the healthcare value chain.
From Drug Distributor to Healthcare Infrastructure
McKesson’s roots go back to 1833, when John McKesson began a wholesale drug business in New York.
Nearly two centuries later, the basic function remains surprisingly recognizable: move healthcare products from manufacturers to the organizations and patients that need them.
The scale, however, has become enormous.
In fiscal 2026, North American Pharmaceutical generated US$336.7 billion in revenue, representing the company’s largest business by far. Oncology & Multispecialty generated another US$48.4 billion, up 31% year over year. Prescription Technology Solutions generated US$5.8 billion, while Medical-Surgical Solutions generated US$11.5 billion.
This gives McKesson a position that is difficult to see from outside the industry.
The company sits between pharmaceutical manufacturers, pharmacies, hospitals, physicians, specialty providers and patients.
It is infrastructure.
The More Interesting Growth Is Happening in Specialty Healthcare
Traditional pharmaceutical distribution is enormous, but its economics are relatively mature.
McKesson’s faster-growing opportunity is specialty healthcare.
Oncology is particularly important.
The company has expanded its presence in community oncology through The US Oncology Network and other provider solutions, while its specialty distribution business connects increasingly complex and expensive therapies with healthcare providers.
In fiscal 2026, the Oncology & Multispecialty segment grew revenue 31% and adjusted segment operating profit 53%.
That distinction matters.
McKesson is not simply moving more products.
It is trying to capture more value around the products it distributes.
Precision Medicine Extends the Strategy
The next step became clearer in August 2026.
McKesson agreed to acquire Precision Medicine Group for approximately US$2.25 billion, adding clinical research and biopharma commercialization capabilities to its Oncology & Multispecialty business.
The acquisition expands McKesson’s role further upstream.
Instead of participating primarily when a medicine is already commercialized and ready to be distributed, the company can increasingly participate in the processes surrounding clinical development, commercialization and specialty care.
That creates a more integrated healthcare platform.
The strategy is particularly logical in oncology, where treatments are increasingly specialized, expensive and dependent on complex clinical and provider networks.
McKesson Is Also Simplifying the Business
At the same time, the company is becoming more focused.
McKesson completed its exit from its European retail and distribution operations in January 2026, ending the company’s European divestiture program.
It is also preparing to separate Medical-Surgical Solutions into an independent publicly traded company.
In June, Apollo completed a US$1.25 billion investment for approximately 13% of MMS, valuing the business at approximately US$13 billion in enterprise value. McKesson retained majority ownership and operating control while preparing the business for a potential separation and IPO.
The message is clear.
McKesson is not trying to own everything it has accumulated over its history.
It is concentrating capital around the areas where management sees stronger growth, margins and strategic relevance.
The Business Is Becoming More Profitable
The enormous revenue figure can be misleading.
McKesson operates a distribution business where revenue is massive but margins are relatively thin.
What matters more is what happens to earnings and cash flow.
In fiscal 2026, adjusted EPS increased 18%, while operating cash flow reached US$6.2 billion and free cash flow reached US$5.4 billion. The company returned US$5.1 billion to shareholders through repurchases and dividends.
McKesson also increased its quarterly dividend by 15% in July 2026, to US$0.94 per share, its tenth consecutive year of dividend growth.
That combination — enormous transaction volume, recurring healthcare demand, improving profitability and substantial cash generation — is one of the reasons McKesson has become a much more interesting company than its traditional wholesaler label suggests.
Fiscal 2027 Is Already Underway
The latest quarter shows that the momentum has continued.
For the first quarter of fiscal 2027, McKesson generated US$105.4 billion in revenue, an 8% increase year over year. Gross profit increased 12% to US$3.7 billion, while operating income reached US$1.3 billion.
The composition of growth is particularly revealing.
North American Pharmaceutical revenue increased 5% to US$86.8 billion.
But Oncology & Multispecialty grew 33%, reaching US$14.2 billion.
Prescription Technology Solutions increased 9%, while Medical-Surgical Solutions grew 4%.
The pattern is consistent with the company’s broader strategy: the traditional pharmaceutical distribution engine remains enormous, while specialty healthcare is growing faster.
The Real Transformation
McKesson began as a drug wholesaler almost two centuries ago.
Today, it is becoming something broader.
Its distribution network gives the company enormous proximity to healthcare providers and pharmacies. Its oncology operations put it closer to specialized treatment. Its technology businesses connect prescription and access workflows. Its biopharma services move it closer to pharmaceutical development and commercialization.
The result is a company positioned across multiple stages of the healthcare economy.
And that may be McKesson’s greatest strategic asset.
Healthcare innovation does not end when a medicine is discovered.
It has to be tested.
Commercialized.
Distributed.
Prescribed.
Delivered.
Administered.
And ultimately reach the right patient.
McKesson increasingly operates across those transitions.
The Company McKesson Is Becoming
The most important question surrounding McKesson is therefore not how much medicine it distributes.
It is how much of the infrastructure surrounding modern healthcare it can control.
The company is using the scale of its pharmaceutical distribution business to expand into areas with greater specialization and potentially higher margins, particularly oncology, multispecialty care and biopharma services.
At the same time, it is simplifying its portfolio and returning capital to shareholders.
That creates a very different picture from the traditional image of a pharmaceutical wholesaler.
McKesson is still moving medicines.
But increasingly, it is also building the infrastructure around the medicines — the providers, technology, specialty services and biopharma capabilities required to move healthcare from innovation to patient access.
That is what makes the company relevant today.
McKesson is not simply part of the healthcare supply chain. It is becoming one of the infrastructure layers underneath it.
Market Snapshot
Company: McKesson Corporation
Founded: 1833
Headquarters: Irving, Texas, United States
Industry: Healthcare Services & Pharmaceutical Distribution
FY2026 Revenue: US$403.4 billion
FY2026 Adjusted EPS: US$39.11
FY2026 Free Cash Flow: US$5.4 billion
Q1 FY2027 Revenue: US$105.4 billion
Q1 FY2027 Revenue Growth: 8%
Q1 FY2027 Oncology & Multispecialty Growth: 33%
FY2026 North American Pharmaceutical Revenue: US$336.7 billion
FY2026 Oncology & Multispecialty Revenue: US$48.4 billion
FY2026 Prescription Technology Revenue: US$5.8 billion
CEO: Brian Tyler
Key Areas: Pharmaceutical Distribution, Oncology, Multispecialty Care, Biopharma Services, Prescription Technology & Medical-Surgical Solutions
Latest Major Acquisition: Precision Medicine Group — approximately US$2.25 billion
